Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Horizon scan of MDS treatments

Alan List • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Antibodies Azacitidine Canakinumab Venetoclax

Alan List, MD, Tampa, FL, discusses what is coming up in terms of treatment for low-risk and high-risk myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Alan List

Inflammation, immune dysregulation and targeting in MDS
Alan List et al. • 24 Jul 2022
0:54
HMAs are the standard, what are their limitations?
Alan List • 5 Mar 2020
1:02
The stages and treatments for myelodysplastic syndromes
Alan List • 5 Mar 2020
0:56
Luspatercept for MDS-associated anemia
Alan List • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals